Fred A. Middleton - Nov 17, 2023 Form 4 Insider Report for CHIMERIX INC (CMRX)

Role
Director
Signature
/s/ Michael Alrutz, Attorney-In-Fact
Stock symbol
CMRX
Transactions as of
Nov 17, 2023
Transactions value $
$16,522
Form type
4
Date filed
11/20/2023, 03:28 PM
Previous filing
Nov 13, 2023
Next filing
Jan 25, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMRX Common Stock Purchase $16.5K +17.3K +20.91% $0.96 100K Nov 17, 2023 Fred A. Middleton Separate Property Trust F1
holding CMRX Common Stock 208K Nov 17, 2023 Direct
holding CMRX Common Stock 2.78M Nov 17, 2023 See footnote F2, F3
holding CMRX Common Stock 532K Nov 17, 2023 See footnote F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9500 to $0.9600, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
F2 The securities are held as follows: 829,046 shares of common stock held by Sanderling Venture Partners V, L.P., 233,134 shares of common stock held by Sanderling V Biomedical, L.P., 155,143 shares of common stock held by Sanderling V Limited Partnership, 138,046 shares of common stock held by Sanderling V Beteiligungs GmbH & Co. KG, 199,853 shares of common stock held by Sanderling V Biomedical Co-Investment Fund, L.P., 329,682 shares of common stock held by Sanderling Venture Partners V Co-Investment Fund, L.P. and 891,189 shares of common stock held by Sanderling V Strategic Exit Fund, L.P. (collectively, the Sanderling V Shares).
F3 The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling V Shares and the Sanderling VI Shares (as defined herein). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4 The securities are held as follows: 498,046 shares of common stock held by Sanderling Venture Partners VI Co-Investment Fund, L.P., 15,431 shares of common stock held by Sanderling VI Beteiligungs GmbH & Co. KG and 18,384 shares of common stock held by Sanderling VI Limited Partnership (collectively, the Sanderling VI Shares).